Amphion Innovations plc

Directorate Change

London and New York, 28 August 2014- Amphion Innovations plc (LSE: AMP) (“Amphion” or the “Company”), the developer of medical and technology businesses, today announces the appointment of Mr Miroslaw Izienicki as Non-executive Director with immediate effect.

Mr Izienicki, age 57, is a career banker with experience of providing high level corporate finance advisory and M&A services, particularly in respect of multi-stakeholder engagements at or near the interface of government and commerce. Mr Izienicki, after having served as Chief Operating Officer, is currently Senior Adviser to Gamma Finance LLP, a provider of advisory services to the alternative investments industry with a focus on illiquid hedge funds. Previously, he was Managing Director of Fifth Capital Group, the London-based think tank and leadership counsel. Prior to Fifth Capital, he was Head of Corporate Finance / M&A at the London international HQ of The Nikko Securities Co Ltd of Tokyo, one of the largest Japanese houses. Mr Izienicki is an alumnus of University of Cambridge and UCL, London.

Miroslaw Izienicki presently holds directorships with Fifth Capital Limited and its subsidiary undertakings Fifth Capital Partners Limited and The Bank of Broad Wealth Limited.

Amphion’s Chief Executive Officer, Richard Morgan, commented on the appointment:  “We are delighted to welcome Mr. Izienicki to the Amphion Board.  We welcome his experience and expertise and are confident he will be a key addition to the company.”

Save as disclosed above, there are no further details required to be disclosed pursuant to schedule 2(g) of the AIM rules.

For further information please contact

Amphion Innovations
Charlie Morgan
+1 212 210 6224

Novella Communications
Tim Robertson / Ben Heath
+44 020 3151 7008

Panmure Gordon Limited
Freddy Crossley / Fred Walsh (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 020 7886 2500

About Amphion Innovations plc
Amphion (LSE: AMP) builds shareholder value in emerging companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

On the web: